{"nctId":"NCT00092677","briefTitle":"An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)","startDateStruct":{"date":"2001-01"},"conditions":["Aortic Stenosis"],"count":1873,"armGroups":[{"label":"EZ/Simva 10/40 mg","type":"EXPERIMENTAL","interventionNames":["Drug: ezetimibe (+) simvastatin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"ezetimibe (+) simvastatin","otherNames":["MK0653A"]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients aged 45 to 85 with mild abnormalities of the aortic valve as confirmed by an echocardiogram.\n\nExclusion Criteria:\n\n* Patients previously in a trial using the study drug, or currently taking any medications that are not allowed in this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events)","description":"Composite endpoint of MCE consists of cardiovascular death, AVR (aortic valve replacement) surgery, CHF(congestive heart failure) as a result of progression of aortic stenosis, nonfatal MI (myocardial infarction), CABG (coronary artery bypass) surgery, PCI (percutaneous coronary intervention), hospitalized unstable angina, and nonhemorrhagic stroke","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"333","spread":null},{"groupId":"OG001","value":"355","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events)","description":"Composite endpoint of AVE (aortic valve events) consists of AVR surgery, CHF (as a result of progression of AS), or cardiovascular death","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"308","spread":null},{"groupId":"OG001","value":"326","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events)","description":"Composite endpoint of ICE (ischemic cardiovascular events) consists of cardiovascular death, nonfatal MI, CABG, PCI, hospitalized unstable angina, and nonhemorrhagic stroke","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cardiovascular Death","description":"Number of participants that experienced cardiovascular death","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"56","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Aortic Valve Replacement (AVR)","description":"Number of participants that experienced aortic valve replacement (AVR)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"267","spread":null},{"groupId":"OG001","value":"278","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS)","description":"Number of participants that experienced Congestive Heart Failure (CHF) due to progression of aortic stenosis (AS)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Nonfatal Myocardial Infarction (MI)","description":"Number of participants that experienced nonfatal myocardial infarction (MI)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Coronary Artery Bypass Grafting (CABG)","description":"Number of participants that experienced coronary artery bypass grafting (CABG)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percutaneous Coronary Intervention (PCI)","description":"Number of participants that experienced percutaneous coronary intervention (PCI)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hospitalization for Unstable Angina","description":"Number of participants that experienced hospitalization for unstable angina","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Nonhemorrhagic Stroke","description":"Number of participants that experienced nonhemorrhagic stroke","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Death (Any Cause)","description":"Number of participants that died (any cause)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"POST_HOC","title":"Death Due to Cancer","description":"Number of participants that died due to cancer","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]}]},{"type":"POST_HOC","title":"Incident Cancer","description":"Number of participants with incident cancer","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"70","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Peak Transaortic Jet Velocity","description":"Mean change from baseline in peak transaortic jet velocity","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.613","spread":"0.586"},{"groupId":"OG001","value":"0.618","spread":"0.612"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change in Time Weighted Average Total Cholesterol From Baseline to End of Follow-up","description":"Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.8","spread":"13.5"},{"groupId":"OG001","value":"-2.7","spread":"11.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change in Time Weighted Average Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to End of Follow-up","description":"Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.8","spread":"18.7"},{"groupId":"OG001","value":"-3.8","spread":"20.6"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change in Time Weighted Average High-density Lipoprotein Cholesterol (HDL-C) From Baseline to End of Follow-up","description":"Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":"17.7"},{"groupId":"OG001","value":"2.5","spread":"16.1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percent Change in Time Weighted Average Triglycerides From Baseline to End of Follow-up","description":"Mean percent change (time-weighted average over follow-up) from baseline: Time-weighted average calculated using values at week 8, week 24, year 1 and every 6 months with time interval (days) between 2 successive values used as the weighting factor. For the first follow-up value, the weight was the number of days from randomization.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.9","spread":"27.6"},{"groupId":"OG001","value":"5.1","spread":"30.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":471},"commonTop":["Aortic valve stenosis","Hypertension","Atrial fibrillation","Dyspnoea","Dizziness"]}}}